metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Observational Cohort Study of Hepatic Encephalopathy After Transjugular Intrahep...
Información de la revista
Vol. 16. Núm. 1.
Páginas 140-148 (enero - febrero 2017)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2201
Vol. 16. Núm. 1.
Páginas 140-148 (enero - febrero 2017)
Open Access
Observational Cohort Study of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Visitas
2201
Michaela Routhu
,
Autor para correspondencia
michaela.routhu@nhs.net

Correspondence and reprint request:
, Vaclav Safka, Sunil Kumar Routhu, Tomas Fejfar§, Vaclav Jirkovsky§, Antonin Krajina||, Eva Cermakova, Petr Hulek§, Ladislav Hosak**,††
* School of Psychiatry, Health Education Wessex, United Kingdom
Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic
School of Psychiatry, Health Education West Midlands, United Kingdom
§ Department of Internal Medicine, University Hospital in Hradec Kralove, Czech Republic
|| Department of Radiology, University Hospital in Hradec Kralove, Czech Republic
Computer Technology Center, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic
** Department of Psychiatry, University Hospital in Hradec Kralove, Czech Republic
†† Department of Psychiatry, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Tablas (4)
Table 1. Descriptive Statistics of quantitative data.
Table 2. Variables before TIPS. Categorical data.
Table 3. Results of logistic regression.
Table 4. Results of Odds Ratio.
Mostrar másMostrar menos
Abstract
Introduction and aim

Hepatic encephalopathy (HE) is a common complication of transjugular intrahepatic portosystemic shunting (TIPS). It is associated with a reduced quality of life and poor prognosis. The aim of this study was to compare two groups of patients who did and did not develop overt HE after TIPS. We looked for differences between these groups before TIPS.

Material and Methods

A study of 895 patients was conducted based on a retrospective analysis of clinical data. Data was analyzed using Fisher's exact test, χ2, Mann Whitney test, unpaired t-test and logistic regression. After the initial analyses, we have looked at a regression models for the factors associated with development of HE after TIPS.

Results

257 (37.9%) patients developed HE after TIPS. Patients’ age, pre-TIPS portal venous pressure, serum creatinine, aspartate transaminase, albumin, presence of diabetes mellitus and etiology of portal hypertension were statistically significantly associated with the occurrence of HE after TIPS (p < 0.01). However, only the age, pre-TIPS portal venous pressure, serum creatinine, presence of diabetes mellitus and etiology of portal hypertension contributed to the regression model. Patients age, serum creatinine, presence of diabetes mellitus and portal vein pressure formed the model describing development of HE after TIPS for a subgroup of patients with refractory ascites.

Conclusion

We have identified, using a substantial sample, several factors associated with the development of HE after TIPS. This could be helpful in further research.

Keywords:
Creatinine
Diabetes mellitus
Ascites
Portal vein pressure
Age
Texto completo
Introduction

Transjugular intrahepatic portosystemic shunt (TIPS) has been widely used in the treatment of patients with portal hypertension. One of the common complications associated with TIPS is the development of hepatic en-cephalopathy (HE).

HE is defined by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases as a brain dysfunction caused by liver insufficiency and/or portosystemic shunting; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma.1

Based on the neurological and psychiatric abnormalities HE is graded from Unimpaired to Grade IV. Grades II-IV are categorised as ‘overt’ grades with clinical findings ranging from lethargy, apathy, disorientation for time, obvious personality change, inappropriate behaviour, dys-praxia and asterixis in Grade II to coma in Grade IV.1

Studies have shown that about 30% of patients developed new or worsened HE after TIPS.2,3 The pooled estimate of new or worsening HE was 32% in the study of Russo, et al.4 Post-TIPS, HE reduces quality of life.5 Furthermore, 10% of post-TIPS HE cases require a liver transplant or die.2 The more severe the HE the smaller the chances of survival.6

Several studies have been conducted to investigate predictors for the development and progress of HE in post-TIPS patients. Several factors, such as: higher patient's age,3,7-12 female sex,13 comorbid diabetes mellitus (DM),7 etiology of liver cirrhosis,7,8,13 non-alcoholic causes of portal hypertension,13,14 ascites as the indication for TIPS,11 hypoalbuminaemia,13,15 high serum creatinine,8 hepatofugal pre-TIPS portal flow,16,17 high Child-Pugh score,8,18 high reduction of the portosystemic pressure gradient,19 reduced liver function,20 and placing an uncovered stent21 have all been variably associated with the post-TIPS HE. However, some of these possible predictors such as: age, sex, stage of cirrhosis, Child-Pugh score, indication for TIPS, hepatic arterial blood flow changes after TIPS or type of stent have been challenged by other studies.15,17,22-27 Some of the studies had sampled less than 100 subjects.8-10,16,19-21

The primary aim was to study the association of preexisting patient factors with the development of post-TIPS HE.

The secondary aim was to consider the subgroup of patients with refractory ascites, where knowing which patients are at high risk of developing HE after TIPS, could perhaps in some cases help to consider the alternative of repeated paracentesis. Repeated paracentesis is a commonly used alternative to TIPS for refractory ascites with lesser risk of HE.28 There has been a call for the predictors of post-TIPS HE to be found, to rationalize clinical decision making in this group of patients.29

Material and MethodsStudy design

This is a single centre, retrospective observational cohort study based on the analysis of clinical data collected prospectively in a departmental database. The research was submitted to the Research and Ethics Committee of the University Hospital who concluded that the project did not require ethical approval as it is a retrospective, anonymous survey.

Study sample

Patients, who underwent TIPS between September 1992 and August 2011, were included in the study. We excluded patients under 18 years of age and patients with an unsuccessful TIPS insertion. We also excluded patients with pre-TIPS HE.

Procedure

At the Internal Medicine Department, TIPS was first introduced in 1992. As this was a new procedure then, clinical data was carefully sampled to ensure the safety of patients was maintained at a high standard. Before the TIPS procedure was performed, the presence of physical co-morbidities, physical examination and blood test results were documented (Table 1 and Table 2). A standard TIPS procedure was performed.30,31

Table 1.

Descriptive Statistics of quantitative data.

Variable  Minimum  Maximum  Mean  Standard Deviation  Units  P Value*  P Value Refractory Ascites* 
Age at TIPS  18.3  83.1  54.5  11.6  years  <0.001  < 0.001 
Pre-TIPS Hepatic Venous Pressure  34  9.7  4.1  mmHg  0.081  0.491 
Pre-TIPS Portal Venous pressure  54  30.6  6.3  mmHg  0.002  0.019 
Pre-TIPS Portal Pressure Gradient  41  20.6  5.7  mmHg  0.049  0.046 
Post-TIPS Hepatic Venous Pressure  29  13.2  4.4  mmHg  0.010  0.049 
Post-TIPS Portal Venous pressure  41  21.4  5.4  mmHg  0.244  0.376 
Post-TIPS Portal Pressure Gradient  24  8.4  3.9  mmHg  0.613  0.777 
Diameter of The Stent  14  10.8  1.2  mm  0.547  0.837 
Shunt Length  20  160  81.1  14.0  mm  0.879  0.145 
Decompression of Shunt  -5  27  9.3  4.3  mmHg  0.138  0.038 
Systolic Blood Pressure  50  190  124.3  19.9  mmHg  0.861  0.548 
Diastolic Blood Pressure  30  120  73.8  12.1  mmHg  0.344  0.471 
Heart Rate  48  142  83.5  15.7  /min.  0.037  0.031 
Sodium  104  152  134.3  6.1  Mmol/L  0.395  0.473 
Serum Creatinine  48  740  100.6  71.9  Micromol/L  < 0.001  0.003 
Serum Bilirubin  654  48.0  62.0  Micromol/L  0.590  0.579 
Conjugated Bilirubin  438  34.6  53.8  Micromol/L  0.956  0.566 
Alanine Aminotransferase  4.7  564.7  67.4  47.0  U/L  0.010  0.185 
Aspartate Transaminase  5.9  588.2  70.6  61.65  U/L  0.008  0.262 
Gamma-Glutamyltransferase  12  929.8  155.9  148.9  U/L  0.047  0.109 
Alkaline Phosphatase  29.4  1588.2  158.8  138.8  U/L  0.217  0.440 
Total Protein  39.9  97.5  65.9  12.1  g/L  0.551  0.807 
Albumin  14.6  51.9  30.8  6.5  g/L  0.006  0.080 
International Normalized Ratio  0.3  11  1.5  0.6  N/A  0.998  0.870 
Total Cholesterol  0.7  8.1  3.3  1.2  Mmol/L  0.486  0.962 
Ammonia  309  62.5  40.6  Micromol/L  0.491  0.599 
Pre TIPS Child-Pugh Points  14  8.3  2.2  N/A  0.020  0.479 
*

P-value refers to the differences between patients with and without HE using the Mann–Whitney test. Significant differences (P <0.01) were marked in bold. P values are uncorrected for multiple comparison.

Table 2.

Variables before TIPS. Categorical data.

Variable  P Value*  P Value Refractory Ascites* 
Diabetes mellitus  < 0.001  0.011 
sex  0.472  0.886 
Etiology of portal hypertension  < 0.001  0.004 
Indication of TIPS  0.381  N/A 
Urgency of TIPS  0.688  0.520 
Type of the Stent (Covered vs. Non-covered)  0.302  0.217 
Two shunts used  0.736  1.000 
Pre TIPS Child-Pugh Class  0.136  0.737 
*

P-value refers to the differences between patients with and without HE using the χ2 and Fisher's exact test. Significant differences (P < 0.01) were marked in bold. P values are uncorrected for multiple comparison.

Uncovered stents were used until 2000, as stentgrafts (covered stents) were not available. Mix of covered and uncovered stents has been used since 2000. Due to the price of the covered stents, covered stents are being given to patients with longer life expectancy and if the patients are due to have a liver transplantation (temporary TIPS).

Shunt patency was assessed using Doppler ultrasound one month after TIPS and then three monthly.32 TIPS revision was indicated in the case of significant stenosis of the shunt. Balloon dilatation or insertion of another stent was performed if needed. All patients in the study had patent shunt during the follow up period.

Assessment of HE

Our information about the development of overt post-TIPS HE was based on close follow up of patients after the TIPS procedure. Interview and a simple task such as asking the patient to provide a signature were used. Collateral information from family gave significant insight into the grade of HE. As this was a clinical setting, no battery of psychometric tests was used. No psychometric tests are needed for diagnosis of overt HE.1

Follow up

Patients had a daily review for 1 week during their in-patient stay after the TIPS procedure and outpatient follow up with a consultant hepatologist at: 1 month, 3 months and 6 months after the TIPS procedure. Further follow up appointments at 3-6 months were made thereafter. This was based on previous reports that most of the patients develop HE during the first 3 months after TIPS.2 Families and patients were educated to contact the hepa-tology service if any signs of HE appeared, and the hepa-tology nurse maintained frequent contact with the patients and their families. Additional urgent appointments with a consultant were provided if any complications, including HE, were suspected, and this was recorded accordingly.

Statistical methods

Data was analyzed using the statistical program SPSS version 19.033 and NCSS 9.34 Statistical significance was taken as p < 0.01 due to higher number of tested variables. We used Fisher exact test and χ2 test for categorical variables, and the Mann Whitney test for quantitative data, to identify factors associated with development of HE. Statistically significant variables were used in the logistic binary regression analysis. For positively skewed values, the natural logarithm was used to improve the model.

We then used unpaired t-test to look for differences between group of patients with diabetes on oral versus insulin treatment, and for differences between group who underwent urgent TIPS.

We then performed a separate analysis for the subgroup of patients with refractory ascites to identify the factors statistically associated with development of hepatic en-cephalopathy for this subgroup (Table 1 and Table 2).

Results

After applying the exclusion criteria (Figure 1), we obtained a final sample of 678 subjects. Most patients in the cohort were male (64%) with alcoholic liver disease (55%) and variceal bleeding (54%). There were 183, 320 and 166 patients with the Child Pugh score A, B and C, respectively. One hundred ninety-two patients had DM (79 on insulin). In 57 cases portal vein thrombosis was present prior to the TIPS procedure. For the purpose of statistical analysis, we have grouped the etiology of portal hypertension into following groups: viral hepatitis, autoimmune hepatitis, alcoholic, cholestatic, vascular/non-cirrhotic, NAFLD/ cryptogenic, rare/congenital, multiple diagnoses/combinations. The descriptive statistics of the sample are summarized in Table 1, Figure 2 and Figure 3.

Figure 1.

Excluded patients.

(0.13MB).
Figure 2.

Etiology of portal hypertension.

(0.13MB).
Figure 3.

Indication for transjugular intrahepatic portosystemic shunt.

(0.13MB).

The team used a covered stent in 234 (34.5%) cases. One hundred twenty-seven (18.7%) of the TIPS insertions were urgent. After TIPS, 257 (37.9%) patients developed HE. Fourteen patients required reduction of the shunt because of the severity of HE. Fifty-three of the patients who had undergone TIPS were later listed for orthotopic liver transplantation. The mean length of follow up after TIPS was 35 months. The mortality in 4 weeks was 11.5%; the mortality in one year was 37%.

We found 7 statistically significant variables associated with development of HE (p < 0.01) (Table 1 and Table 2). High age, pre-TIPS portal venous pressure, serum creat-inine, aspartate transaminase, low albumin, presence of DM and etiology of portal hypertension were all associated with the development of HE after TIPS. The regression model describing the development of HE after TIPS is summarized in Table 3 and Table 4. In terms of the etiology of portal hypertension, 95% of vascular/non-cirrhotic patients were HE free after TIPS. On the other hand, 64% of patients with viral hepatitis and 65% of patients with alcoholic liver disease did develop new HE after TIPS.

Table 3.

Results of logistic regression.

Model for any HE (Percent correctly classified = 68.0%)
  No HE  HE  Total 
No HE  261  122  383 
HE  75  158  233 
Total  336  280  616 
Model for Refractory Ascites (Percent correctly classified = 62.5%)
  No HE  HE  Total 
No HE  72  44  116 
Total  100  92  192 
Table 4.

Results of Odds Ratio.

  Odds Ratio  Confidence Interval 
Model for any HE     
Age at TIPS  1.047  1.026 - 1.068 
Creatinine  1.005  1.002 - 1.009 
Cholestatic etiology of portal hypertension  0.455  0.129 - 1.604 
Multiple causes for portal hypertension  0.330  0.092 - 1.183 
Idiopathic liver disease as etiology of portal hypertension  0.554  0.189 - 1.626 
Alcoholic liver cirrhosis as etiology of portal hypertension  0.462  0.171 - 1.250 
Rare / Congenital etiology of portal hypertension  0.517  0.113 - 2.372 
Vascular / Non-cirrhotic etiology of portal hypertension  0.074  0.013 - 0.437 
Viral hepatitis as etiology of portal hypertension  1.220  0.380 - 3.919 
Patients on oral treatment for diabetes mellitus  1.487  0.923 - 2.397 
Patients on insulin treatment for diabetes mellitus  1.863  1.070 - 3.244 
Pre-TIPS portal venous pressure  1.048  1.015 - 1.081 
Model for refractory ascites     
Age at TIPS  1.057  1.021 - 1.094 
Creatinine  1.004  1.000 - 1.009 
Patients on oral treatment for diabetes mellitus  1.997  0.831 - 4.802 
Patients on insulin treatment for diabetes mellitus  0.691  0.280 - 1.706 
Pre-TIPS portal venous pressure  1.062  1.002 - 1.125 

For patients with refractory ascites, the main variables associated with development of HE after TIPS were age and serum creatinine. The regression model describing the development of HE after TIPS in this subgroup is summarized in Table 3 and Table 4. The etiology of portal hypertension was statistically significant for the subgroup however due to smaller frequencies it did not contribute to the regression model. 100% of the of vascular/non-cirrhotic patients were HE free after TIPS and 65% of patients with viral hepatitis developed HE after TIPS. The alcoholic cause to portal hypertension was not significantly associated with HE after TIPS. Pre-TIPS portal venous pressure and DM were bordering on being significant and did contribute to the regression model.

The urgency of TIPS was not shown to be statistically significant. From our observations we hypothesized that this might be due to patients undergoing urgent TIPS being younger than those undergoing non-urgent TIPS. This difference was confirmed (p = 0.018, unpaired t-test).

DM was a strong predictor of HE. Interestingly, the patients treated with insulin did not statistically differ from the group of patients on diet or oral anti-diabetics (p > 0.8, unpaired t-test).

Discussion

This is a study of the association of preexisting variables on the development of HE. We confirmed the importance of age, pre-TIPS portal venous pressure, serum creatinine, DM and etiology of portal hypertension in the incidence of post-TIPS HE.

The regression models used were able to successfully sort around 60% cases. Therefore the models are suitable for description of the factors associated with development of HE and not for its prediction.

The association between hepatic encephalopathy and albumin levels, creatinine and aspartate transaminase is probably due to severity of liver damage.35,36 The pre-TIPS portal venous pressure, likely an indicator of severity of portal hypertension,37 was associated with hepatic encephalopathy after TIPS.

It was reported that older people are more likely to develop hepatic encephalopathy, possibly due to age-related vulnerability of the brain.38 This is in concordance with our findings that age is a very important predictor of HE after TIPS.

DM is associated with reduced psychomotor functions, a lower attention span and impaired memory.39 The pre-existing vulnerability of the brain could explain development of hepatic encephalopathy after TIPS for both older people and individuals with DM. TIPS affecting the homeostasis could trigger the HE if there was a preexisting condition.

Due to the benefit of having large data, we were able to confirm that previously reported sex differences in development of HE in small samples3 were more likely random findings.

There was no significant difference between covered and non-covered stents in terms of association with development of HE after TIPS in this study.

The percentage of alcohol-related portal hypertension cases in our sample was consistent with world litera-ture.40,41

The etiology of liver cirrhosis complicated by portal hypertension is sometimes difficult to establish exactly in each individual. The self-reported alcohol consumption in the subgroup of patients who drink alcohol but also meet the criteria for NAFLD presents a diagnostic challenge. People in general have a tendency to report lower alcohol consumption than is their real consumption.42

NAFLD is one of the newer diagnoses.43 Therefore, some patients who might have been in the past given diagnosis of idiopatic cirrhosis might be nowadays diagnosed with NAFLD. This is the case especially for number of patients suffering from diabetes mellitus type II.44

It might be expected that the TIPS procedures performed urgently, and often associated with disrupted homeostasis, would be associated with HE. However, the fact that these patients were younger than those undergoing non-urgent TIPS could explain the result (as above).

Majority of the TIPS were done for variceal bleeding. However, there were only 18.7% urgent TIPS in the whole sample. This is because some of the TIPS were done preventively for patients with a history of multiple variceal bleedings. Nowadays, due to the improvements in endoscopic interventions, the number of patients indicated to preventive TIPS is decreasing.45

Ascites as the indication for TIPS was not associated with development of HE in our sample, unlike in other studies.11 As patients suffering with ascites usually have, as a group, bigger liver damage, one would expect that these patients would be at higher risk of developing HE after TIPS. The patients with portal hypertension from vascular reasons (Budd-Chiari syndrome) might still have a good liver function and hence lower risk of HE. We presume that the reason why indication for TIPS was not statistically significantly associated with the development of HE might be because some very unwell patients were included in the study overall.

In our sample, 65% of patients with alcoholic liver disease developed new HE after TIPS. This is in contrast with previous findings where non-alcoholic causes of portal hypertension were associated with HE after TIPS.13,14 We believe, that the likelihood of developing HE after TIPS depends on whether the person stops drinking alcohol after TIPS or not. If the person continues drinking, their cirrhosis is likely to get worse and their brain is likely to get more damaged. Around the time of TIPS procedure, the patients are offered interventions for alcohol problems when in hospital, and patients are more motivated to stop drinking. The key issue is that we are missing data about who abstained from alcohol after TIPS. This can cause a bias in our study as well as in the other mentioned studies.13,14 It is therefore difficult to conclude whether the alcoholic or non-alcoholic cause predisposed patients to developing HE after TIPS. 64% of patients with viral hepatitis disease did develop new HE after TIPS. The viral hepatitis more often progressed and led to worsening of clinical picture and development of HE.

In terms of the study limitations, the study was retrospective, which brings limitations such as inability to control for confounding factors, some missing data and lost to follow up. The TIPS is highly specialized procedure and therefore the centre covered a large geographic area making follow up attendance difficult for some patients from distant cities, leading to slightly higher lost to follow up.

As TIPS was used since 1992, its target patient group was not well established in the beginnings. This has led to some outliers in the sample, such as the patient with bi-lirubin of 654. Gradually the most unwell patients from the Child-Pugh grade C group started being excluded from TIPS referrals. Nowadays, TIPS is not indicated for patients with Child Pugh score over 12.

TIPS procedure is completed for all patients in a standard way. Very most of the patients had 10mm stent inserted. However, the impact on the Portal Pressure Gradient is individual. The lower mean of Portal Pressure Gradient might be also caused by some outliers in the minimum range of the measurements.

High reduction of the portosystemic pressure gradient was reported to lead to development of HE.19 The higher the reduction of the portosystemic pressure gradient, the lower the risk of bleeding46 and the better are the chances that ascites will reduce. Clinicians are aware that the higher the reduction of the portosystemic pressure gradient, the higher the chances of developing HE due to reduced blood flow through liver.

The study presents real world data. This brings its own advantages and limitations. The diagnosis of hepatic en-cephalopathy was made by hepatologists. In our opinion, this is not necessarily a limitation of the study. In practice, the diagnosis of overt HE is frequently made by hepatolo-gists. HE prophylaxis was not recorded for statistical analysis due to the variability in individual prescribing based on clinical judgment. The results therefore represent the risks for an uncontrolled population of patients undergoing TIPS, rather than for a treatment naive population.

It was not the aim of the study to follow up of the development of HE in detail. It would be beneficial to see, in future prospective studies, how the symptoms of HE develop over time. Further studies could also focus on comparing the blood results at the time of any episodes of HE.

The study focused on differences in baseline characteristics of patients who did, and who did not, develop HE after TIPS. Since the study focused on correlation, it cannot draw conclusions about a causality between the baseline characteristics and development of HE after TIPS. It merely describes that people with a certain baseline characteristics are more likely to develop HE after TIPS, whether those characteristics are directly involved in the development of the HE or not.

We hope this large real-world-data study will help to conduct future studies focusing on specific predictors of HE after TIPS.

Acknowledgments

The authors would like to thank Mr Christopher West, Honorary Senior Fellow of the Department of Public Health and Policy, University of Liverpool, for the valuable statistical support.

Abbreviations

  • DM: diabetes mellitus.

  • HE: hepatic encephalopathy.

  • TIPS: transjugular intrahepatic portosystemic shunting.

Financial Support

The study was supported by the research grant IGA NS/10363-3 (by the Ministry of Health).

References
[1.]
American Association for the Study of Liver Diseases, European Association for the Study of the Liver.
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.
J Hepatol, 61 (2014), pp. 642-659
[2.]
Masson S., Mardini H.A., Rose J.D., Record C.O..
Hepatic en-cephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience.
QJM, 101 (2008), pp. 493-501
[3.]
Zuckerman D.A., Darcy M.D., Bocchini T.P., Hildebolt C.F..
En-cephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors.
AJR Am J Roentgenol, 169 (1997), pp. 1727-1731
[4.]
Russo M.W., Sood A., Jacobson I.M., Brown R.S..
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
Am J Gastroenterol, 98 (2003), pp. 2521-2527
[5.]
Campbell M.S., Brensinger C.M., Sanyal A.J., Gennings C., Wong F., Kowdley K.V., Mccashland T., et al.
Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy.
Hepatology, 42 (2005), pp. 635-640
[6.]
Stewart C.A., Malinchoc M., Kim W.R., Kamath P.S..
Hepatic en-cephalopathy as a predictor of survival in patients with end-stage liver disease.
Liver Transpl, 13 (2007), pp. 1366-1371
[7.]
Stefánková J., Hulek P., Babu A., Cermáková E., Safka V., Stefanek J., Fejfar T., et al.
Hepatic encephalopathy due to TIPS-retrospective study.
Hepatogastroenterology, 54 (2007), pp. 480-484
[8.]
ter Borg P.C., Hollemans M., Van Buuren H.R., Vleggaar F.P., Groeneweg M., Hop W.C., Laméris J.S..
Transjugular Intra-hepatic Portosystemic Shunts: Long-term Patency and Clinical Results in a Patient Cohort Observed for 3–9 Years.
Radiology, 231 (2004), pp. 537-545
[9.]
Riggio O., Merlli M., Pedretti G., Servi R., Meddi P., Lionetti R., Rossi P., et al.
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.
Dig Dis Sci, 41 (1996), pp. 578-584
[10.]
Sanyal A.J., Freedman A.M., Shiffman M.L., Purdum P.P., Luketic V.A., Cheatham A.K..
Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.
Hepatology, 20 (1994), pp. 46-55
[11.]
Mamiya Y., Kanazawa H., Kimura Y., Narahara Y., Yamate Y., Nakatsuka K., Sakamoto C..
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Hepatol Res, 30 (2004), pp. 162-168
[12.]
Hassoun Z., Deschênes M., Lafortune M., Dufresne M.P., Perreault P., Lepanto L., Gianfelice D., et al.
Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy.
Am J Gastroenterol, 96 (2001), pp. 1205-1209
[13.]
Somberg K.A., Riegler J.L., Laberge J.M., Doherty-Simor M.M., Bachetti P., Roberts J.P., Lake J.R..
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors.
Am J Gastroenterol, 90 (1995), pp. 549-555
[14.]
Rössle M., Deibert P., Haag K., Ochs A., Olschewski M., Siegerstetter V., Hauenstein K.H., et al.
Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endos-copy plus propranolol for prevention of variceal rebleeding.
Lancet, 349 (1997), pp. 1043-1049
[15.]
Bahn E., Nolte W., Kurth C., Ramadori G., Rüther E., Wiltfang J..
Quantification of the electroencephalographic theta/alpha ratio for the assessment of portal-systemic encephalopathy following implantation of transjugular intrahepatic portosys-temic stent shunt (TIPSS).
Metab Brain Dis, 17 (2002), pp. 19-28
[16.]
François E., García-Pagán J.C., Bru C., Feu F., Gilabert R., Escorsell A., Bosch J., et al.
[Effects of percutaneous intra-hepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension].
Gastro-enterol Hepatol, 20 (1997), pp. 1-4
[17.]
Deng D., Liao M.S., Qin J.P., Li X.A..
Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
Hepatobiliary Pancreat Dis Int, 5 (2006), pp. 232-236
[18.]
Bai M., Han G.H., Yuan S.S., Yin Z.X., He C.Y., Wang J.H., Qi X.S., et al.
[Early hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: the risk factors and long-time survival].
Zhonghua Gan Zang Bing Za Zhi, 19 (2011), pp. 498-501
[19.]
Nägele T., Seeger U., Pereira P., Seitz D., Klose U., Kaiser S., Eisold M., et al.
[MR proton spectroscopy to monitor the concentration changes in cerebral metabolites following a TIPS placement].
Rofo, 170 (1999), pp. 298-303
[20.]
Nolte W., Wiltfang J., Schindler C., Münke H., Unterberg K., Zumhasch U., Figulla H.R., et al.
Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
Hepatology, 28 (1998), pp. 1215-1225
[21.]
Bureau C., Pagan J.C., Layrargues G.P., Metivier S., Bellot P., Perreault P., Otal P., et al.
Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.
[22.]
Stefánková J., Fejfar T., Safka V., Hulek P., Krajina A., Fendrichová M..
[Hepatic encephalopathy after TIPS-retrospective study].
Vnitr Lek, 48 (2002), pp. 390-395
[23.]
Angeloni S., Merli M., Salvatori FM¯, De Santis A., Fanelli F., Pepino D., Attili A.F., et al.
Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results.
Am J Gastroenterol, 99 (2004), pp. 280-285
[24.]
Thuluvath P.J., Bal J.S., Mitchell S., Lund G., Venbrux A..
TIPS for management of refractory ascites: response and survival are both unpredictable.
Dig Dis Sci, 48 (2003), pp. 542-550
[25.]
Amarapurkar D.N., Punamiya S., Patel N.D..
An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India.
Ann Hepatol, 5 (2006), pp. 103-108
[26.]
Patel N.H., Sasadeusz K.J., Seshadri R., Chalasani N., Shah H., Johnson M.S., Namyslowski J., et al.
Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postpro-cedural encephalopathy and mortality.
J Vasc Interv Radiol, 12 (2001), pp. 1279-1284
[27.]
Pomier-Layrargues G., Villeneuve J.P., Deschênes M., Bui B., Perreault P., Fenyves D., Willems B., et al.
Transjugular intrahe-patic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.
Gut, 48 (2001), pp. 390-396
[28.]
Ginès P., Arroyo V..
Paracentesis in the management of cir-rhotic ascites.
J Hepatol, 17 (1993), pp. 14-18
[29.]
D’Amico G., Luca A., Morabito A., Miraglia R., D’Amico M..
Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.
Gastroenterology, 129 (2005), pp. 1282-1293
[30.]
Gordon J.D., Colapinto R.F., Abecassis M., Makowka L., Langer B., Blendis L.M., Taylor B., et al.
Transjugular intrahepatic porto-systemic shunt: a nonoperative approach to life-threatening variceal bleeding.
Can J Surg, 30 (1987), pp. 45-49
[31.]
Krajina A., Hùlek P., Eliás P., Michl A., Heger L., Volfová M., Niangová I., et al.
[Transjugular intrahepatic portosystemic shunt].
Cor Vasa, 35 (1993), pp. 157-161
[32.]
Zizka J., Eliás P., Krajina A., Michl A., Lojík M., Ryska P., Masková J., et al.
Value of Doppler Sonography in Revealing Transjugular Intrahepatic Portosystemic Shunt Malfunction.
AJR Am J Roentgenol, 175 (2000), pp. 141-148
[33]
IBM Corp.: Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp
[34]
Hintze J: NCSS 9. NCSS, LLC. Kaysville, Utah, USA. www.NCSS.com
[35.]
Wiesner R., Edwards E., Freeman R., Harper A., Kim R., Kamath P., Kremers W., et al.
Model for end-stage liver disease (MELD) and allocation of donor livers.
Gastroenterology, 124 (2003), pp. 91-96
[36.]
Child C.G., Turcotte J.G..
Surgery and portal hypertension.
The liver and portal hypertension, pp. 50-64
[37.]
Kumar A., Sharma P., Sarin S.K..
Hepatic venous pressure gradient measurement: time to learn!.
Indian J Gastroenterol, 27 (2008), pp. 74-80
[38.]
Quero J.C., Hartmann I.J., Meulstee J., Hop W.C., Schalm S.W..
The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis.
Hepatology, 24 (1996), pp. 556-560
[39.]
Awad N., Gagnon M., Messier C..
The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function.
J Clin Exp Neuropsychol, 26 (2004), pp. 1044-1080
[40.]
Friedman S., Schiano T..
Cirrhosis and its sequelae.
Cecil Textbook of Medicine, 22, pp. 936-944
[41.]
Crawford J.M..
Liver and biliary tract.
Robbins and Cotran Pathologic Basis of Disease, 7, pp. 877-938
[42.]
Stockwell T., Zhao J., Greenfield T., Li J., Livingston M., Meng Y..
Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: Identification of consistent biases across four English-speaking countries.
Addiction, 7 (2016),
[43.]
Rinella M.E., Loomba R., Caldwell S.H., Kowdley K., Charlton M., Tetri B., Harrison S.A..
Controversies in the Diagnosis and Management of NAFLD and NASH.
Gastroenterol Hepatol (N Y), 10 (2014), pp. 219-227
[44.]
Leite N.C., Villela-Nogueira C.A., Cardoso C.RL., Salles G.F..
Nonalcoholic fatty liver disease and diabetes: From physio-pathological interplay to diagnosis and treatment.
World J Gastroenterol, 20 (2014), pp. 8377-8392
[45.]
Pomier-Layrargues G., Villeneuve J., Deschenes M., Bui B., Perreault P., Fenyves D., Willems B., et al.
Transjugular intra-hepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.
Gut, 48 (2001), pp. 390-396
[46.]
Biecker E., Roth F., Heller J., Schild H.H., Sauerbruch T., Schepke M..
Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis.
Eur J Gastroenterol Hepatol, 19 (2007), pp. 846-852
Copyright © 2017. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos